Download Full Text (261 KB)
AngioMax is a single dose heparin alternative introduced in 2002 that is used in cardiac patients undergoing percutaneous intervention (PCI). Bivalirudin costs $377 per dose; heparin is less than $15 per dose. Noting practice variations, the Cath Lab set out to eliminate unnecessary pharmacy cost for PCI patients by:
- Using current literature to inform clinical care
- Standardizing practice
- Using data to track and guide implementation
Bivaliruidin, Heparin, Cost, Percutaneous intervention, Standardized practice
Cardiology | Other Nursing | Pharmacoeconomics and Pharmaceutical Economics
Scepaniak, Scott M. and Patterson, Kristi, "Decreasing Unnecessary Pharmacy Cost in the Cath Lab" (2018). Nursing Posters. 103.